Evidence map›Paper›PMID 29898397›Full record

ArticleCell reports2018

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.

David Wang, Jason Quiros, Kelly Mahuron, Chien-Chun Pai, Valeria Ranzani, Arabella Young, Stephanie Silveria, Tory Harwin, Arbi Abnousian, Massimiliano Pagani and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed, 1 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

211 citing papers in PubMed, 1 synthesis or guideline pooled it, 303 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Tuning epigenetics to enhance cancer virotherapy.Acta pharmaceutica Sinica. B · 2026
    Review
  6. Article
  7. Article
  8. Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026
    Review
  9. Review
  10. Review
  11. Intratumoral TScience immunology · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

151 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

David WangDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA; Division of Pediatric Hematology and Oncology, University of California, San Francisco Benioff Children's Hospital, San Francisco, CA 94158, USA.
Jason QuirosDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Kelly MahuronDepartment of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA.
Chien-Chun PaiDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.
Valeria RanzaniIstituto Nazionale Genetica Molecolare (INGM) "Romeo ed Enrica Invernizzi," Milan 20122, Italy.
Arabella YoungDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Stephanie SilveriaDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Tory HarwinDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Arbi AbnousianDepartment of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Massimiliano PaganiIstituto Nazionale Genetica Molecolare (INGM) "Romeo ed Enrica Invernizzi," Milan 20122, Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milano 20129, Italy.
Michael D RosenblumDepartment of Dermatology, University of California, San Francisco, San Francisco, CA 94143, USA.
Frederic Van GoolDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Lawrence FongDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
Jeffrey A BluestoneDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA. Electronic address: jeff.bluestone@ucsf.edu.
Michel DuPageDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA. Electronic address: dupage@berkeley.edu.
University of California, San Francisco · USIstituto Nazionale Genetica Molecolare · ITParker Institute for Cancer Immunotherapy · USUniversity of California, Berkeley · USUCSF Benioff Children's Hospital · US

Funding

Research Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0M
Functional Manipulation of Memory Regulatory T cells in SkinDP2AR068130 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENBLUM, MICHAEL DAVID · 2014 to 2014
$2.4M
IMMUNOMODULATION OF TRANSPLANT REJECTION BY ANTI-CD3 MABR01AI046643 · NIAID · UNIVERSITY OF CHICAGO · PI BLUESTONE, JEFFREY A · 2000 to 2015
$1.8M
NCI NIH HHS T32 CA128583NIAID NIH HHS R01 AI046643NIAMS NIH HHS DP2 AR068130
6 · The paper itself

Abstract

Regulatory T cells (Tregs) are critical for maintaining immune homeostasis, but their presence in tumor tissues impairs anti-tumor immunity and portends poor prognoses in cancer patients. Here, we reveal a mechanism to selectively target and reprogram the function of tumor-infiltrating Tregs (TI-Tregs) by exploiting their dependency on the histone H3K27 methyltransferase enhancer of zeste homolog 2 (EZH2) in tumors. Disruption of EZH2 activity in Tregs, either pharmacologically or genetically, drove the acquisition of pro-inflammatory functions in TI-Tregs, remodeling the tumor microenvironment and enhancing the recruitment and function of CD8

Indexed as

AnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorEnhancer of Zeste Homolog 2 ProteinForkhead Transcription FactorsHumansInterferon-gammaLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLMice, KnockoutNeoplasmsT-Lymphocytes, RegulatoryTumor MicroenvironmentTumor Necrosis Factor-alphaEnhancer of Zeste Homolog 2 ProteinForkhead Transcription FactorsFoxp3 protein, mouseInterferon-gammaTumor Necrosis Factor-alpha

Identifiers

PMID29898397
PMCPMC6094952
OpenAlexW2808497725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.